Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review

• Published in: Curēus (Palo Alto, CA) Vol. 15; no. 9; p. e46032
• Main Authors: Hossain, Md Fahad, Kharel, Manish, Akter, Mahfuza, Parajuli, Bibek, Yadav, Indresh, Mandal, Nitesh, Mandal, Anjali, Aziz, Syed Nurul
• Format: Journal Article
• Language: English
• Published: Palo Alto Cureus Inc 26.09.2023; Cureus
• Subjects: Biomarkers; Clinical trials; Hematology; Immunotherapy; Internal Medicine; Intervention; Ligands; Lymphoma; Medical personnel; Monoclonal antibodies; Oncology; Quality of life; Response rates; Systematic review; Targeted cancer therapy; Toxicity; United States > US
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.46032

Classical Hodgkin lymphoma (cHL) has achieved high cure rates as a result of recent advancements in treatment. However, recurring or relapsed illness still poses a therapeutic challenge. Immune checkpoint inhibitor pembrolizumab, which targets PD-1, is now being commonly used as part of immunotherapy for recurrent and relapsed cHL. We found eight appropriate articles through systematic search and conducted in-depth analysis to find insights into the effectiveness and safety profiles of pembrolizumab by analyzing clinical trial data in patients with recurrent and relapsed cHL. Analysis of the studies shows that response rates, progression-free survival, and patient-reported quality of life have all significantly improved. However, immune-related consequences are among the adverse outcomes. The necessity for continued study is highlighted by the variation in reported adverse events and follow-up times. Clinicians, researchers, and other healthcare professionals can use this study as a resource to provide knowledgeable and individualized patient care in cHL.